Table 3 Antimicrobial susceptibility [MIC₉₀ (mg/L), % susceptible, % resistant] of methicillin-resistant S. aureus, methicillin-susceptible S. aureus, extended-spectrum β-lactamase-positive E. coli and K. pneumoniae and multidrug-resistant Acinetobacter spp., collected in Mexico, T.E.S.T. 2005–2012

S. aureus, MRSA

n = 112

n = 349

n = 461

 Levofloxacin

32

5.4

94.6

≥64

8.0

90.8

≥64

7.4

91.8

 Linezolid

2

100

0.0

2

100

0.0

2

100

0.0

 Minocycline

0.5

100

0.0

1

97.4

1.4

1

98.0

1.1

 Tigecycline

0.25

100

–

0.5

100

–

0.5

100

–

 Vancomycin

1

100

0.0

1

100

0.0

1

100

0.0

S. aureus, MSSA

n = 182

n = 379

n = 561

 Levofloxacin

0.5

95.1

3.3

2

89.2

7.9

1

91.1

6.4

 Linezolid

4

100

0.0

4

100

0.0

4

100

0.0

 Minocycline

1

99.5

0.5

0.5

98.9

0.8

0.5

99.1

0.7

 Tigecycline

0.25

100

–

0.25

100

–

0.25

100

–

 Vancomycin

1

100

0.0

1

100

0.0

1

100

0.0

E. coli, ESBL-positive

n = 134 (43/91)

n = 333 (9/324)

n = 467 (52/415)

 Amikacin

16

94.8

0.7

32

87.7

6.3^a

32

89.7

4.7

 Amoxicillin-clavulanate

32

26.1

29.1

32

16.8

40.2^a

32

19.5

37.0

 Ampicillin

≥64

0.7

99.3

≥64

2.1

97.6

≥64

1.7

98.1

 Cefepime

≥64

23.9

58.2

≥64

26.1

60.7

≥64

25.5

60.0

 Ceftriaxone

≥128

0.0

98.5

≥128

3.6

95.8

≥128

2.6

96.6

 Imipenem

0.5

97.7

2.3

–

[9]

[0]

0.25

98.1

1.9

 Levofloxacin

≥16

3.0

94.8

≥16

7.8

90.7

≥16

6.4

91.9

 Meropenem

0.12

100

0.0

0.25

97.2

1.5

0.25

97.8

1.2

 Minocycline

16

70.1

17.9

≥32

47.7

36.0^a

≥32

54.2

30.8

 Piperacillin-tazobactam

32

88.8

2.2

128

63.4

15.3^a

128

70.7

11.6

 Tigecycline

0.5

100

0.0

0.5

100

0.0

0.5

100

0.0

K. pneumoniae, ESBL-positive

n = 59 (15/44)

n = 154

n = 213 (15/198)

 Amikacin

≥128

76.3

16.9

≥128

59.1

32.5

≥128

63.8

28.2

 Amoxicillin-clavulanate

≥64

25.4

40.7

≥64

13.6

53.9

≥64

16.9

50.2

 Ampicillin

≥64

1.7

96.6

≥64

0.0

100

≥64

0.5

99.1

 Cefepime

32

81.4

11.9

≥64

53.9

36.4^a

≥64

61.5

29.6

 Ceftriaxone

≥128

3.4

91.5

≥128

0.0

98.1

≥128

0.9

96.2

 Imipenem

1

100

0.0

–

–

–

–

–

–

 Levofloxacin

≥16

45.8

49.2

≥16

44.8

51.3

≥16

45.1

50.7

 Meropenem

0.5

95.5

4.5

0.5

93.5

4.5

0.5

93.9

4.5

 Minocycline

≥32

52.5

32.2

≥32

40.3

41.6

≥32

43.7

39.0

 Piperacillin-tazobactam

≥256

49.2

25.4

≥256

37.0

37.0

≥256

40.4

33.8

 Tigecycline

2

96.6

0.0

2

94.8

0.6

2

95.3

0.5

Acinetobacter spp., MDR

n = 33 (7/26)

n = 161

n = 194 (7/187)

Amikacin

≥128

12.1

84.8

≥128

6.8

83.2

≥128

7.7

83.5

Cefepime

≥64

6.1

48.5

≥64

14.9

63.4

≥64

13.4

60.8

Ceftazidime

≥64

0.0

93.9

≥64

4.3

91.3

≥64

3.6

91.8

Ceftriaxone

≥128

0.0

100

≥128

1.9

96.3

≥128

1.5

96.9

Imipenem

–

[6]

[1]

–

–

–

–

–

–

Levofloxacin

≥16

0.0

90.9

≥16

1.2

95.7

≥16

1.0

94.8

Meropenem

16

34.6

53.8

≥32

29.8

64.6

≥32

30.5

63.1

Minocycline

2

90.9

6.1

≥32

62.1

28.6^a

≥32

67.0

24.7

Piperacillin-tazobactam

≥256

9.1

84.8

≥256

3.1

92.5

≥256

4.1

91.2